An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC: CBD, nabiximols) oromucosal spray

Etges T, Karolia K, Grint T, Taylor A, Lauder H, Daka B, Wright S. Therapeutics and clinical risk management 2016; 12:1667-1675

ARTICLE IDENTIFIERS

DOI: 10.2147/TCRM.S115014 PMID: unavailable PMCID: not available

JOURNAL IDENTIFIERS

LCCN: 2006243617 pISSN: 1176-6336 eISSN: 1178-203X OCLC ID: 60534739 CONS ID: not available US National Library of Medicine ID: 101253281

This article was identified from a query of the SafetyLit database.